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Mks1 in Concert with TOR Signaling
Negatively Regulates RTG Target Gene
Expression in S. cerevisiae
served reduced basal expression of CIT2 and DLD3
when this mks1 strain was grown in rich media (YPD),
a condition that is known to repress activation of the
pathway [7, 11].
We decided to pursue these observations and dis-
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Davis, California 95616 rupted MKS1 in the common laboratory strain W303
[12]. To our surprise, however, both CIT2 and DLD3 were
expressed at very high levels when these mks1 cells
were grown in YPD, in comparison to wild-type cellsSummary
(Figure 1A, compare lanes 1 and 2). Because the regula-
tion of RTG target gene expression has been reportedThe target of rapamycin (TOR) signaling pathway
to vary in different strains of yeast [13], we reasonedallows eukaryotic cells to regulate their growth in re-
one possible explanation for the difference between oursponse to nutritional cues [1, 2]. In S. cerevisiae, TOR
results and those reported by Shamji et al. was ourcontrols the expression of genes involved in several
choice of strain background. We therefore deletednutrient-responsive biosynthetic pathways [3–7]. In
MKS1 in two additional strain backgrounds: DBY8721particular, we have demonstrated that TOR negatively
(Laboratory of David Botstein, Stanford University), aregulates a concise cluster of genes (termed RTG tar-
derivative of S288c [14]; and 2000 (Microbia, Cam-get genes) that encode mitochondrial and peroxisomal
bridge, MA), a derivative of 1278 [15]. In each case,enzymes required for de novo amino acid biosynthesis
deletion of MKS1 again resulted in strong expression of[7]. TOR acts in part by regulating the subcellular local-
CIT2 and DLD3 (Figure 1A, lanes 3–6).ization of the Rtg1/Rtg3 transcription factor complex.
To compare our results directly with those of ShamjiNuclear entry of this complex requires the cytoplasmic
et al., we obtained and analyzed the same mks1 strainprotein Rtg2, whose precise function has remained ill
used in their study [6]. In agreement with their publisheddefined. Here we establish that the likely role of Rtg2
data, we observed reduced basal expression of CIT2is to antagonize the activity of another protein, Mks1,
and DLD3 in this strain (Figure 1A, lane 8). Furthermore,which we demonstrate is itself a negative regulator
no increase in expression of these genes resulted follow-of RTG target gene activation. Results of epistasis
ing treatment of cells with rapamycin (data not shown).analyses suggest that Rtg2 and Mks1 act downstream
Interestingly, we also observed that this particularof TOR and upstream of Rtg1 and Rtg3. Moreover, we
mks1 strain but not the mks1 strains we constructedfind that Mks1 phosphorylation responds to TOR as
required exogenous glutamine (or glutamate) for growthwell as to each of the Rtg1-Rtg3 proteins, indicative
(data not shown). Glutamate (or glutamine) auxotrophyof complex regulation within this branch of TOR signal-
is a well-established phenotype associated with an im-ing. In addition to RTG target genes, microarray analy-
paired RTG pathway [11].sis reveals robust expression of lysine biosynthetic
The mks1 strain used by Shamji et al. [6] was origi-genes in mks1 cells, which depends on a functional
nally constructed in the laboratory of Evelyn Dubois [8].RTG pathway. This latter result provides a molecular
In an effort to resolve the above discrepancies, we ob-explanation for the previous identification of MKS1 as
tained and analyzed an original isolate of this mks1LYS80, a negative regulator of lysine biosynthesis [8].
strain, where strong expression of CIT2 and DLD3 was
observed (Figure 1B). Moreover, this mks1 strain dis-
Results and Discussion played no growth defect in the absence of glutamate or
glutamine (data not shown). Based on these combined
The MKS1 gene encodes a cytoplasmic protein that results, we conclude that Mks1 negatively regulates
has been implicated in a number of diverse biological RTG target gene expression. We believe further that it
processes, including ras signaling [9], the lysine biosyn- is likely that the particular isolate of the Dubois mks1
thetic pathway [8], and nitrogen metabolism [10]. The strain used by Shamji et al. has acquired an additional
precise cellular function of this protein has remained mutation(s) that impairs activation of this pathway.
elusive, however. We became interested in Mks1 follow- We wanted to confirm that increased expression of
ing the report by Shamji et al. that this protein acts CIT2 and DLD3 observed in mks1 cells was mediated
downstream of TOR as a positive regulator of RTG target by RTG components rather than through activation of
gene expression [6]. This conclusion was based on re- an alternative pathway. Accordingly, we monitored ex-
sults of global gene expression analyses, where the RTG pression of these genes in strains deleted for MKS1
target genes CIT2 and DLD3 failed to be induced in an as well as each of the three RTG genes RTG1–3. No
mks1 strain treated with rapamycin, a specific inhibitor expression of CIT2 or DLD3 was observed in rtg1
of the TOR kinases [6]. This is in contrast to wild-type mks1 or rtg3mks1 cells, confirming that expression
cells, where rapamycin treatment results in strong ex- of these genes in mks1 cells requires the Rtg1/Rtg3
pression of these genes [6, 7]. These authors also ob- transcription factors (Figure 1D, lanes 6 and 8). In striking
contrast, CIT2 and DLD3 were expressed to the same
extent in both mks1 as well as rtg2 mks1 cells,1 Correspondence: tpowers@ucdavis.edu
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Figure 1. Mks1 Is a Negative Regulator of the
RTG Pathway
(A and B) Northern blot analysis of specified
mRNAs isolated from wild-type (WT) and
mks1 cells, derived from several different
strain backgrounds, as indicated. To delete
MKS1, the entire coding region of this gene
was replaced with the LEU2 gene from plas-
mid pRS305 [17], using standard gene re-
placement techniques [18]. 1278SS denotes
strains obtained from the Schreiber labora-
tory and used in the study by Shamji et al.
[6]. 1278ED denotes strains obtained from
the Dubois laboratory and used in the study
by Feller et al. [8]. (C) Analysis of growth prop-
erties of strains on SCD agar plates that con-
tained (left panel) or lacked (right panel) gluta-
mine. Cells were grown in YPD to OD600 
1.0, washed with sterile 50 mM potassium
phosphate (pH 7.5), serially diluted and spot-
ted out onto plates, and incubated for 3 days
at 30C. SCD media contained 0.8% yeast
nitrogen base without amino acids (pH 5.5),
2% dextrose, and 0.2% glutamine where ap-
propriate. In addition, to supplement the
auxotrophic requirements of these strains,
SCD media was also supplied with appro-
priate amino acids, adenine, and uracil as de-
scribed [20]. (D) Northern blot analysis of
specified mRNAs isolated from wild-type and
mutant strains deleted for the indicated
gene(s). In (A), (B), and (D), cells were grown
in YPD (1% yeast extract, 2% peptone, 2%
dextrose) to mid-log phase (0.5 OD600/ml), and
total RNA was isolated and analyzed as de-
scribed [19]. (E) Localization of Rtg1-GFP in
wild-type (WT) versus mks1 cells. Cells were
transformed with plasmid pRTG1-GFP [7] and
grown to mid-log phase (0.5 OD600/ml) in SCD
media that contained glutamine but lacked
uracil (to select for plasmid maintenance). Im-
ages documenting GFP localization were col-
lected on a Nikkon Eclipse E600 microscope
using a 60 oil immersion objective (Nikkon)
and recorded with a CCD camera (Hama-
matsu) using an exposure time of 2 s. Image
analysis was performed using Open Lab soft-
ware (Improvision, Boston, MA). All strains in
(C)—(E) were derived from the W303 back-
ground [12].
demonstrating that Rtg2 is not required for the expres- sequestered in the cytoplasm in the presence of gluta-
mate and/or glutamine [7]. Constitutive expression ofsion of these target genes in the absence of Mks1 (Figure
1D, lanes 5 and 7). These expression patterns of CIT2 RTG target genes in mks1 cells suggested that the
Rtg1/Rtg3 complex might be localized in the nucleusand DLD3 also correlated with the growth properties of
the different mutants on selective solid media. Thus, even under rich nutrient conditions. To test this prediction
directly, we monitored the localization of an Rtg1-GFPwhereas mks1, rtg2, and rtg2 mks1 cells all grew
on agar plates containing ammonia and glutamine as fusion protein in mks1 cells grown in glutamine-con-
taining rich media. Indeed, we observed that Rtg1-GFPnitrogen sources, only mks1 and rtg2 mks1 cells
grew on plates that lacked glutamine (Figure 1C). Taken was localized primarily in the nucleus in mks1 cells
versus in the cytoplasm in wild-type cells (Figure 1E).together, these results indicate that, in the absence of
Mks1 activity, the RTG pathway is expressed constitu- We also observed that an Rtg3-GFP fusion protein was
localized in the nucleus in mks1 cells under these sametively, and Rtg2 becomes dispensable for growth, at
least under these experimental conditions. As expected, conditions (data not shown). Taken together, these re-
sults indicate that Mks1 is involved in retaining the Rtg1/deletion of MKS1 failed to suppress the glutamine auxot-
rophy of either rtg1 or rtg3 cells (Figure 1C). Rtg3 complex in the cytoplasm in response to glutamine
availability.We have shown previously that the RTG pathway is
controlled in part by regulated nucleocytoplasmic trans- To extend the results of the above expression studies,
we determined global transcriptional changes that re-port of Rtg1 and Rtg3, where these proteins become
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Figure 2. Mks1 Regulates the Activity of a
Concise Number of Genes
(A) Scatter plot analysis shows genome-wide
differences in gene expression between WT
and mks1 cells in the W303 background.
The y axis depicts cDNA samples derived
from WT cells and labeled with Cy3 dye,
whereas the x axis depicts cDNA samples
derived from mks1 cells and labeled with
Cy5 dye. Dashed lines mark the boundaries
of mean difference ratios in gene expression
equal to 3.0 between the two strains. (B)
Genes preferentially expressed in mks1
cells. Listed genes displayed a mean differ-
ence ratio of 3.0 or greater (log10 scale) in
two of the three strain backgrounds (an ex-
ception is PYC1, known to be regulated in
part by the RTG pathway [7], where the differ-
ence in expression in two of the strains is less
than 3-fold). Similar results were observed in
two independent experiments. (C) Increased
expression of LYS gene expression in mks1
cells requires a functional RTG pathway.
Northern blot analysis of specified mRNAs
isolated from strains described in Figure 1D.
In (A)–(C), cells were grown to OD600  0.5
in YPD. Preparation of fluorescently labeled
cDNA and microarray analysis was per-
formed exactly as described [7].
sulted from the loss of Mks1 function. To this end, DNA stitutively active, namely, in mks1 and rtg2 mks1
cells (Figure 2C). Indeed, the patterns of expression ofmicroarrays covering 95% of the yeast genome were
probed with fluorescently labeled cDNAs prepared from these genes in the various mutant strains were virtually
identical to the patterns observed for CIT2 and DLD3wild-type and mks1 cells, using each of the three strain
backgrounds described above. Of the more than 6200 (compare Figures 1D and 2C). Thus, we conclude that
increased LYS gene expression is a secondary eventgenes examined, only a very small number of genes
displayed significant differences in expression (3-fold that follows activation of the RTG pathway in cells lack-
ing Mks1. Consistent with this conclusion, mks1 cellsor greater), and most were elevated in mks1 cells (Fig-
ures 2A and 2B). In addition to CIT2 and DLD3, this list have increased levels of -ketoglutarate, a product of
the RTG pathway and an inducer of lysine biosynthesisincludes other known RTG targets, most notably, genes
encoding enzymes associated with the early steps of [8]. In an extension of these results, microarray analysis
of the different mutant strains showed that all changesthe TCA cycle (Figure 2B) [7, 11]. Strikingly, genes in-
volved in the lysine biosynthetic pathway were also in gene expression observed in mks1 cells could be
attributed to constitutive activation of the RTG pathwaystrongly induced in mks1 cells (Figure 2B). This result
is consistent with the previous identification of MKS1 (our unpublished data).
Having established that Mks1 negatively regulatesas LYS80, a negative regulator of lysine biosynthesis
[8]. In agreement with our present findings, an analysis RTG target gene expression, we wanted to determine
the relationship between this protein and TOR signaling.of lys80 cells revealed an increase in intracellular levels
of lysine as well as lysine biosynthetic enzymes [8]. Results from two independent lines of experimentation
suggest that Mks1 functions as part of the TOR pathway.We considered two possible explanations as to why
genes involved in the LYS pathway are induced in mks1 First, no change in expression of CIT2 or DLD3 was
observed following addition of rapamycin to mks1 orcells: (1) Mks1 inhibits expression of these genes di-
rectly, or (2) expression of these genes is a consequence rtg2 mks1 cells (Figures 3A and 3B, lanes 5 through
8). Such absence of any additive effect on RTG targetof constitutive activation of the RTG pathway. To distin-
guish between these possibilities, we used Northern gene expression when both TOR and Mks1 function is
inhibited is consistent with each component actingblotting to examine the expression of three LYS genes
in strains that were deleted for both MKS1 and RTG1–3. within the same pathway. Second, Western blot analysis
revealed a reproducible shift in the electrophoretic mo-Increased expression of these LYS genes was observed
only under conditions where the RTG pathway was con- bility of an epitope-tagged version of Mks1 (Mks1-HA3),
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from a slower to a faster migrating form, following treat-
ment of wild-type cells with rapamycin (Figure 4A, com-
pare lanes 1 and 2). Because this shift to a faster mobility
form could be mimicked by addition of phosphatase to
cell extracts in vitro (Figure 4B, lane 1), we conclude
that Mks1 is a phosphoprotein and, moreover, that its
phosphorylation state responds to TOR signaling.
Western blot analysis also revealed that the phos-
phorylation state of Mks1 is influenced by the Rtg1-Rtg3
proteins (Figure 4A). In extracts prepared from either
rtg1 or rtg3 cells, only the faster migrating form of
Mks1-HA3 was observed, indicating that Mks1 is consti-
tutively hypophosphorylated in the absence of the Rtg1
or Rtg3 transcription factors (Figure 4A, lanes 3 and 7).
In stark contrast, the mobility of Mks1-HA3 shifted to
a much slower and heterogenous form in rtg2 cells,
suggesting Mks1 is hyperphosphorylated in the absence
of Rtg2 (Figure 4A, lane 5). Whether these complexities
in the pattern of Mks1 phosphorylation reflect physical
interactions with one or more of the Rtg1–3 proteins
remains to be determined.
We have demonstrated previously that rapamycin
treatment mimics removal of glutamine from the growth
media, with respect to RTG target gene activation [7].
Thus, to extend our present findings, we monitored CIT2
mRNA levels in wild-type as well as in rtg2, mks1,
and rtg2 mks1 cells in media that either contained or
lacked glutamine (Figure 3C). Here the overall pattern
of CIT2 expression observed was very similiar to the
pattern described above when rapamycin was added
to cells grown in rich media (compare Figures 3A and
3C). In particular, high levels of CIT2 expression was
observed in both mks1 and rtg2 mks1 cells in the
presence of glutamine; moreover, these levels did not
increase following removal of glutamine from the growth
media (Figure 3C, compare lanes 5 through 8). There-
fore, we conclude that, in the absence of Mks1 activity,
RTG target gene expression is largely uncoupled from
regulation by glutamine. By contrast, wild-type cells
showed normal glutamine-dependent inhibition of CIT2
expression (Figure 3C, compare lanes 1 and 2).
We also wanted to verify the physiological signifi-
cance of rapamycin-induced changes in the phosphory-
lation state of Mks1. We reasoned that if dephosphoryla-
tion of Mks1 is relevant to the mechanism of RTG target
gene activation, then a similar effect should be observed
when cells are grown in media lacking glutamine. In-
deed, we observed a reproducible increase in the mobil-
ity of Mks1-HA3 when wild-type cells were treated with
rapamycin or grown in glutamine-deficient media (Figure
4C, compare lanes 1 through 3). Glutamine depletion
in combination with rapamycin addition produced an
Figure 3. Testing the Relationship between Mks1, TOR Signaling,
additive effect on the mobility of Mks1-HA3, confirmingand Glutamine
that both conditions contribute to Mks1 dephosphoryla-(A) Northern blot analysis of specified mRNAs isolated from wild-
tion (Figure 4C, lane 4).type and mutant strains, as indicated. Cells were grown in YPD
to OD600  0.5 and were treated with rapamycin (0.2 g/ml final
concentration) for 30 min, where indicated. All strains were derived
from W303. To control for the effects of rapamycin on the expression (C) Influence of glutamine deprivation on CIT2 expression in wild-
of the RTG target genes CIT2 and DLD3, the r protein mRNA RPL30 type and mutant strains, as indicated. Cells were grown in YPD to
(formally RPL32) was also analyzed, which displays reduced expres- OD600  0.5. Each culture was then divided into two, and cells were
sion in the presence of drug, in agreement with our previous obser- then pelleted and resuspended in SCD media that either contained
vations [19]. or lacked glutamine, as indicated. Cells were incubated for 30 min,
(B) Quantitation of data from (A), where the y axes indicate relative harvested, and then processed for Northern blot analysis, probing
mRNA levels, normalized to ACT1 levels. for the specified mRNAs.
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Many of the functional interactions we have character-
ized can be described in terms of a formal pathway
where TOR is linked to RTG target gene expression
through interplay between Rtg2 and Mks1 (Figure 5A).
According to this model, the primary function of Rtg2
is to inhibit Mks1, which, in turn, negatively regulates
Rtg1 and/or Rtg3, most likely by preventing nuclear lo-
calization of the Rtg1/Rtg3 complex. This model can
account for why Rtg2 is not essential for expression of
RTG target genes in the absence of Mks1. Moreover, it
can explain why these target genes are not induced
when rapamycin is added to rtg2 cells (Figures 3A and
3B); thus, in the absence of Rtg2, Mks1 becomes a
constitutive inhibitor whose activity is uncoupled from
control by TOR and by nitrogen availability.
A number of additional observations exist, however,
that cannot be reconciled with a simple linear pathway.
Most significantly, we observed substantial dephos-
phorylation of Mks1 in rapamycin-treated and/or gluta-
mine-depleted rtg2 cells, demonstrating that Mks1 re-
mains responsive to both TOR and nutrient status in the
absence of Rtg2 (Figure 4A, lanes 5 through 6, and
Figure 4C, lanes 5 through 8). This result is reminiscent
of our previously published observation that rapamycin-
induced changes in the phosphorylation state of Rtg3
also persist in rtg2 cells [7]. Indeed, we have found
that rapamycin-induced changes in Rtg3 phosphoryla-
tion persist in mks1cells as well (our unpublished data).
Taken together, these data suggest that additional func-
tional interactions exist between TOR and individual
components involved in RTG target gene regulation
(summarized in Figure 5B). Understanding the signifi-
cance of these interactions will require identifying the
sites of phosphorylation in Mks1 and determining their
importance to RTG target gene regulation.
How might Mks1 function, in mechanistic terms, to
regulate RTG target gene expression? Clues to an an-
swer come from previous studies where the intracellular
localization of Rtg1 and Rtg3 was examined in different
mutant backgrounds [7, 16]. In particular, Rtg3 is local-
ized constitutively in the cytoplasm in rtg2 cells but isFigure 4. Demonstrating that Mks1 Is a Phosphoprotein Whose
instead concentrated in the nucleus in both rtg1 andPhosphorylation State Responds to TOR Signaling, to Rtg1-Rtg3,
and to Glutamine rtg1 rtg2 cells [7, 16]. These results indicate that Rtg1
(A) Wild-type and rtg1-rtg3 strains expressing Mks1-HA3 were plays an important role in holding the Rtg1/Rtg3 com-
grown in YPD to OD600  0.5 and were treated with rapamycin (0.2 plex within the cytoplasm and, moreover, that this is a
g/ml final concentration) for 30 min, where indicated. Extracts were step regulated by Rtg2. Based on our results presented
prepared, and Western blot analysis was performed as described
here, we suggest that Mks1 is also involved in this regu-[7], using anti-HA monoclonal antibody (raw ascites fluid, 16B12,
lated nuclear transport step. Butow and coworkers haveBabco) to detect Mks1-HA3. Signal was detected using the Renais-
demonstrated that Rtg3 contains the nuclear localiza-sance chemiluminescence detection system (New England Nuclear
Life Sciences, Boston, MA). Three copies of the coding region for tion signal (NLS) essential for nuclear import of the Rtg1/
the hemagglutinin (HA) epitope were introduced at the C terminus Rtg3 complex [16]. Thus, one attractive possibility is
of MKS1, using the PCR-based method described [21]. As template that Mks1 controls access to this NLS, for example,
for PCR, plasmid pFA6a-3HA-HIS3MX6 was used [21], which con-
by regulating a conformational change within the Rtg1/tains the S. pombe HIS3 homolog.
Rtg3 complex. Alternatively, Mks1 may interact directly(B) Control experiment demonstrating that Mks1-HA3 is a phospho-
with the NLS to prevent access to nuclear transport fac-protein. Extracts were prepared from wild-type cells and were either
mock treated or treated with five units of calf intestinal alkaline tors. According to this model, the role of Rtg2 would be
phosphatase (CIP; Roche Molecular Biochemicals), according to
the instructions of the manufacturer. For comparison, a rapamycin-
treated extract was prepared from wild-type cells and loaded on
the same gel, as indicated. in SCD media that contained or lacked glutamine, as indicated. Each
(C) Comparing the influence of rapamycin and/or glutamine depriva- culture was then divided into two again, and rapamycin was added
tion on Mks1 phosphorylation. Wild-type and rtg2 strains express- at a final concentration of 0.2 g/ml to half of the samples, as
ing Mks1-HA3 were grown in YPD to OD600  0.5. Each culture was indicated. Cells were incubated for 30 min and were processed for
then divided into two, and cells were pelleted and resuspended Western blot analysis.
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Figure 5. Architecture of the RTG Branch of
the TOR Pathway
(A) Summary of functional relationships be-
tween components involved in RTG target
gene regulation identified in this study. Inhibi-
tion of TOR signaling with rapamycin or loss
of Mks1 function results in activation of RTG
target gene expression. In contrast, loss of
Rtg2 function alone results in constitutive in-
hibition of the pathway. Activation of the RTG
pathway in mks1 cells leads to events de-
noted below the dotted line, including in-
creased production of -ketoglutarate and
subsequent activation of the LYS pathway.
In this respect, rapamycin treatment is more
restricted, in that only events above the dot-
ted line are likely to be affected. The explana-
tion for this is that rapamycin treatment
causes widespread changes in cellular physi-
ology, including a sharp decrease in transla-
tional initiation [22], which is expected to pre-
vent the actual synthesis of early TCA cycle
enzymes.
(B) Relationships between RTG regulatory
components, inferred from analyses of the
phosphorylation states of Mks1 and Rtg3 un-
der different conditions. Data for Mks1 phosphorylation is from Figure 4. Data for Rtg3 phosphorylation is from [7] as well as our unpublished
data. We note that, in many cases, TOR-dependent effects appear to be antagonistic to those of other RTG regulatory components. The
significance of these relationships remains to be determined.
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